Presented herein are methods of producing "personalized" secretome compositions suitable for secretome based therapy to be administered to a specific individual and/or specific group of individuals. The iPSCs and/or iPSC-derived cells, and any iPSC-derived compositions derived therefrom, are identified as compatible with a specific individual or specific group of individuals using an identification of a cell type indicative of compatibility such as an HLA match and/or ABO blood match and/or RHD blood group match. The identified compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a suitable donor. The retrieved compatible cells are then used to derive the "personalized" iPSC-derived secretome compositions, that comprise the complete secretome or a subset of the secretome suitable for treatment of a specific individual and/or specific group of individuals.
